Status:
COMPLETED
Study in Healthy Adults Evaluating PF-07202954
Lead Sponsor:
Pfizer
Conditions:
Non-Alcoholic Fatty Liver Disease
Liver Fibrosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label des...
Eligibility Criteria
Inclusion
- healthy subjects (all 3 Parts)
- evidence of steatosis on FibroScan (Part 2 only)
- BMI 17.5 to 30.5 kg/m2 (Part 1, Part 3)
- BMI 17.5 to 35.4 kg/m2 (Part 2)
Exclusion
- evidence of clinically significant disease
- subjects on chronic medications
- clinically significant, abnormal laboratory results, vital signs, or cardiac conduction abnormalities
- contraindication to MRI (Part 2, only)
Key Trial Info
Start Date :
May 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 17 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04857437
Start Date
May 13 2021
End Date
September 17 2021
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Haven Clinical Research Unit
New Haven, Connecticut, United States, 06511